Core Characteristics
- Live attenuated viral vaccine.
- Contains minimum 1000 infective units of attenuated virus per dose.
- Lacks preservatives, increasing susceptibility to bacterial contamination.
- Available as standalone, measles-rubella combination, or measles-mumps-rubella combination.
Composition And Strains
- Edmonston-Zagreb strain propagates on human diploid cell culture.
- Schwarz strain propagates in chick-embryo fibroblasts.
- Requires reconstitution with supplied sterile diluent prior to administration.
Administration And Storage
- Dose volume strictly measures 0.5 mL.
- Administered via subcutaneous route.
- Preferred site involves right upper arm at deltoid insertion or anterolateral thigh.
- Lyophilized powder requires storage between 2°C and 8°C.
- Highly sensitive to heat and light exposure.
- Reconstituted vaccine mandates discarding within 4 to 6 hours to prevent toxic shock syndrome from staphylococcal contamination.
Immunization Schedule
Universal Immunization Program
- Employs measles-rubella combination vaccine.
| Dose Sequence | Age Of Administration |
|---|
| First dose | 9 to 12 months (minimum 270 completed days) |
| Second dose | 16 to 24 months |
Indian Academy Of Pediatrics Guidelines
- Recommends measles-mumps-rubella formulation.
| Dose Sequence | Age Of Administration |
|---|
| First dose | 9 months |
| Second dose | 15 to 18 months |
| Third dose | 4 to 5 years |
Catch-Up And Outbreak Protocols
- Outbreak administration permits early dosing at 6 months.
- Early outbreak dose remains uncounted; requires standard 9-month dose administration.
- Unimmunized children require two doses separated by minimum 4-week interval.
- Post-exposure prophylaxis utilizes measles-mumps-rubella vaccine within 72 hours of exposure in immunocompetent hosts.
Immunogenicity And Efficacy
- Single dose median vaccine effectiveness measures 84% at 9 to 11 months.
- Single dose median vaccine effectiveness increases to 92.5% beyond 12 months.
- Maternal antibody interference causes primary vaccine failure in 15% of infants vaccinated at 9 months.
- Second dose induces protective immunity in 95% of primary non-responders.
Adverse Effects And Contraindications
Adverse Reactions
- Minor local pain and tenderness occur within 24 hours.
- Mild fever develops in 5% to 15% of recipients 7 to 12 days post-vaccination.
- Transient macular rash appears 7 to 10 days post-vaccination in 2% of recipients.
- Rare complications include thrombocytopenic purpura occurring in 1 per 30,000 vaccinees.
- Toxic shock syndrome risk increases significantly if reconstituted vaccine exceeds 4-hour to 6-hour usage window.
Contraindications
- Severe immunocompromised states, including symptomatic human immunodeficiency virus.
- Systemic high-dose corticosteroid therapy exceeding 14 days.
- Pregnancy mandates strict avoidance.
- Recent receipt of immunoglobulin-containing blood products necessitates vaccination delay.
